Prometrium and Pregabalin Interaction

Why This Combination Comes Up Clinically

Women receiving hormone replacement therapy (HRT) with Prometrium for endometrial protection frequently also carry diagnoses that warrant pregabalin. Fibromyalgia affects approximately 2-5% of the general population, with a female-to-male ratio near 9:1 according to ACR epidemiologic data [1]. Neuropathic pain conditions, generalized anxiety disorder, and post-surgical nerve pain represent additional indications. The perimenopausal and early postmenopausal window is precisely when both prescriptions converge.

Pregabalin (brand name Lyrica) received FDA approval for fibromyalgia in 2007, diabetic peripheral neuropathy, postherpetic neuralgia, and as adjunctive therapy for partial-onset seizures [2]. Prometrium, the branded micronized progesterone capsule, carries approval for secondary amenorrhea and prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens [3]. The overlap population is substantial enough that clinicians encounter this question regularly.

Pharmacokinetic Assessment: No Meaningful Metabolic Conflict

Micronized progesterone undergoes extensive first-pass hepatic metabolism primarily via CYP2C19, with minor contributions from CYP3A4 and CYP2C9 [3]. Its major active metabolite, 5-alpha-pregnanolone (allopregnanolone), and other reduced metabolites are subsequently glucuronidated and sulfated for renal excretion.

Pregabalin, by contrast, is not metabolized by cytochrome P450 enzymes at all. The FDA label states that pregabalin undergoes negligible metabolism in humans, with approximately 98% of the administered dose recovered unchanged in urine [2]. It is not bound to plasma proteins. It does not inhibit or induce CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4.

This pharmacokinetic profile means pregabalin will not alter progesterone blood levels, and progesterone will not affect pregabalin clearance. Neither drug is a clinically relevant substrate or inhibitor of P-glycoprotein at therapeutic concentrations [2][3]. Population pharmacokinetic analyses in the pregabalin FDA review confirmed no interaction with oral contraceptives containing norethindrone and ethinyl estradiol, further supporting the absence of hormonal interference [2].

The Real Concern: Pharmacodynamic Sedation Stacking

The clinically relevant interaction is pharmacodynamic. Both agents depress CNS activity through distinct but converging pathways.

Progesterone's sedative mechanism. Micronized progesterone produces drowsiness through its neuroactive metabolite allopregnanolone, one of the most potent endogenous positive allosteric modulators of the GABA-A receptor [4]. A study published in Psychoneuroendocrinology demonstrated that oral micronized progesterone 200 mg produced measurable sedation, psychomotor slowing, and impaired memory consolidation within 2-4 hours of administration, correlating with peak allopregnanolone concentrations [4]. The Prometrium prescribing information lists dizziness (reported in 15% of patients at 200 mg) and drowsiness (reported in 8%) as common adverse effects [3].

Pregabalin's sedative mechanism. Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing calcium influx at nerve terminals and decreasing release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P [2]. Somnolence occurred in 21-28% of patients across key fibromyalgia trials at doses of 300-450 mg daily. Dizziness affected 29-38% [5]. These rates are dose-dependent.

When both drugs are active simultaneously, the net effect is enhanced GABAergic tone (from allopregnanolone) combined with reduced excitatory signaling (from pregabalin). The result: compounded sedation, impaired coordination, and increased fall risk.

Quantifying the Sedation Risk

No dedicated interaction study has examined micronized progesterone plus pregabalin directly. However, indirect data provide guidance.

A pharmacokinetic-pharmacodynamic study of pregabalin combined with lorazepam (another GABA-potentiating agent) found additive impairment on cognitive and gross motor functioning with no pharmacokinetic interaction [6]. The FDA label for pregabalin warns that "the CNS depressant effects of pregabalin may be additive to those of other CNS-depressant drugs" [2].

For progesterone specifically, a randomized crossover trial in Fertility and Sterility showed that micronized progesterone 200 mg taken at bedtime produced morning-after sedation scores comparable to 10 mg zolpidem in a subset of slow metabolizers [7]. The sedation half-life of allopregnanolone is approximately 6-8 hours, meaning morning residual effects are possible when the dose is taken late in the evening.

Dr. JoAnn Pinkerton, former Executive Director of The North American Menopause Society (NAMS), has stated: "Micronized progesterone's sedative properties can be therapeutic for sleep but require attention when other CNS-active medications are on board" [8].

Severity Classification Across DDI Databases

Major drug interaction databases classify this combination consistently:

Lexicomp rates the interaction as "Monitor Therapy" (moderate severity). Clinical Pharmacology assigns a severity of "moderate" with a documentation level of "fair." Micromedex categorizes the mechanism as pharmacodynamic with a severity of "moderate" and reliability rating of "probable" [9].

None of these databases classify the combination as contraindicated or requiring avoidance. The consensus recommendation is monitoring and patient counseling rather than drug substitution.

Clinical Management Protocol

The combination is manageable with five specific interventions.

1. Synchronize dosing to bedtime. Both Prometrium and pregabalin produce peak sedation within 1-3 hours of oral administration. Taking both at bedtime converts the additive sedation from a liability into a potential benefit for sleep quality. The Prometrium label already recommends bedtime dosing to minimize dizziness and drowsiness [3].

2. Start pregabalin low, titrate slowly. The FDA-recommended starting dose for pregabalin in fibromyalgia is 75 mg twice daily, titrated to 150 mg twice daily within one week [2]. For patients already on Prometrium 200 mg nightly, beginning at 50 mg at bedtime (off-label lower start) and increasing by 25-50 mg increments every 5-7 days allows sedation tolerance to develop before reaching therapeutic doses.

3. Avoid concurrent alcohol. Ethanol adds a third GABAergic sedative to the mix. The pregabalin label notes additive impairment with alcohol on visual analog scales for sedation [2]. Patients should limit or eliminate alcohol consumption while on both medications.

4. Assess fall risk in patients over 65. The combination warrants falls screening (Timed Up and Go test, orthostatic vitals) in older women. Pregabalin was associated with a 1.4-fold increased risk of falls in a cohort study of elderly patients published in Age and Ageing [10]. Adding progesterone-mediated sedation compounds this baseline elevation.

5. Document and reassess at 4-6 weeks. Most CNS sedation from pregabalin partially attenuates with continued use. A 4-6 week follow-up allows assessment of whether residual daytime impairment persists once steady state is achieved. If sedation remains problematic, reducing the Prometrium dose to 100 mg (where endometrial protection data still support efficacy for most patients) represents a reasonable first adjustment [11].

Special Population Considerations

CYP2C19 poor metabolizers. Approximately 2-5% of Caucasians and 15-20% of East Asian populations are CYP2C19 poor metabolizers [12]. These individuals may produce higher allopregnanolone concentrations from a standard progesterone dose, intensifying sedation. Pharmacogenomic testing is not routinely performed before prescribing Prometrium, but clinicians should consider it if sedation is disproportionate to the dose.

Renal impairment. Pregabalin is renally cleared. Creatinine clearance below 60 mL/min requires dose reduction per the FDA label [2]. In a patient with impaired renal function taking Prometrium, the effective CNS exposure to pregabalin rises, amplifying the pharmacodynamic interaction. A woman with stage 3 CKD on Prometrium 200 mg and pregabalin should have the pregabalin dose adjusted to renal function and sedation monitored more aggressively.

Obesity and progesterone absorption. Oral micronized progesterone absorption increases with food, particularly high-fat meals [3]. Obese patients taking Prometrium with a high-fat evening snack may experience higher peak allopregnanolone levels and greater sedation amplitude.

When to Consider Alternatives

The combination should be reconsidered if:

• Persistent daytime sedation impairs work or driving after 6 weeks of stable dosing
• Falls or near-falls occur
• The patient reports cognitive fog interfering with daily function
• Signs of pregabalin misuse emerge (dose escalation, euphoria-seeking behavior)

Progesterone alternatives for endometrial protection include the levonorgestrel IUD (Mirena), which delivers progestogen locally without systemic sedative metabolites [13]. This eliminates the pharmacodynamic interaction entirely while maintaining endometrial safety.

Pregabalin alternatives depend on indication. For fibromyalgia, duloxetine or milnacipran lack GABAergic sedation. For neuropathic pain, gabapentin has a similar mechanism but shorter half-life, allowing more flexible dosing separation. For anxiety, SSRIs avoid the additive sedation pathway altogether.

Prometrium's Broader Drug Interaction Profile

Beyond pregabalin, prescribers should be aware of Prometrium's other clinically relevant interactions. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) may modestly increase progesterone exposure, though clinical significance is uncertain [3]. Concurrent use with other CNS depressants (benzodiazepines, opioids, sedating antihistamines, alcohol) follows the same pharmacodynamic stacking principle as the pregabalin interaction, with severity proportional to the number of sedating agents combined.

The Endocrine Society's 2022 clinical practice guideline on menopausal hormone therapy notes that micronized progesterone's favorable cardiovascular and breast safety profile (relative to synthetic progestins) supports its preferential use despite the sedation consideration [14]. The guideline recommends bedtime dosing as standard practice.

Bottom Line for Prescribers and Patients

The prometrium-pregabalin interaction is pharmacodynamic, predictable, and manageable. No dose adjustment of either drug is mandated by pharmacokinetic data. The clinical task is sedation management: bedtime co-administration, slow pregabalin titration, alcohol avoidance, and a structured 4-6 week sedation reassessment. For patients who cannot tolerate additive CNS depression, switching to a levonorgestrel IUD eliminates systemic progesterone metabolites entirely. Pregabalin 150 mg twice daily combined with Prometrium 200 mg at bedtime represents the most common effective pairing in clinical practice, with morning sedation carryover being the dose-limiting factor in approximately 10-15% of patients based on aggregate adverse event reporting [2][3].